How to Help Your Patients Find Orilissa in Stock: A Provider's Guide

Your Patient Has a Prescription. Now What?

You've determined that Orilissa (Elagolix) is the right choice for your patient's endometriosis pain. The clinical decision is made — but the access journey is just beginning. For many patients, the hardest part of Orilissa isn't taking it. It's finding it.

As a specialty, brand-name medication with a cash price of $1,200–$1,700 per month, Orilissa is not routinely stocked at most retail pharmacies. Patients often encounter pharmacy stockouts, prior authorization requirements, and specialty pharmacy mandates that can delay or derail treatment.

This guide provides actionable steps you and your staff can take to smooth that process.

Current Availability Landscape

Orilissa is not in a formal shortage as of 2026. AbbVie continues to manufacture and distribute it. However, retail pharmacy availability remains inconsistent due to:

• Low demand at the store level: A typical CVS or Walgreens may have zero or one patient on Orilissa, making it uneconomical to stock.
• High unit cost: Pharmacies bear financial risk when stocking expensive medications that may not be picked up.
• Specialty pharmacy channeling: Many payers require dispensing through designated specialty pharmacies.
• No generic available: Elagolix remains a single-source product from AbbVie.

Why Patients Can't Find Orilissa

Understanding the patient's perspective helps you anticipate problems. Here's what patients typically experience:

1. They take the prescription to their local pharmacy.
2. The pharmacy doesn't stock it and says it will need to be ordered (1–3 days).
3. Insurance requires prior authorization, adding more days.
4. The PA may be denied initially, requiring an appeal.
5. If approved, the insurance company may require the patient to use a specific specialty pharmacy they've never heard of.
6. The patient may abandon the prescription out of frustration.

Studies consistently show that access barriers for specialty medications contribute to high prescription abandonment rates. Proactive intervention at the point of prescribing can make a significant difference.

What Providers Can Do: 5 Actionable Steps

Step 1: Initiate Prior Authorization Before the Patient Leaves

Don't wait for the pharmacy to trigger the PA process. Initiate it from your office the same day you write the prescription. Use electronic prior authorization (ePA) tools when available — they can reduce turnaround from days to hours.

Common PA criteria for Orilissa include:

• Confirmed diagnosis of endometriosis
• Documentation of failed or inadequate response to first-line therapies (NSAIDs, hormonal contraceptives)
• Prescriber is an OB/GYN or specialist

Having this documentation ready before submitting the PA significantly improves approval rates.

Step 2: Send the Prescription to the Right Pharmacy

Before sending the prescription to the patient's regular retail pharmacy, check whether their insurance plan requires a specialty pharmacy. If so, send it directly there. This avoids the frustrating back-and-forth of having the retail pharmacy reject it and the patient having to start over.

If the patient's plan doesn't require a specialty pharmacy, consider sending the prescription to a pharmacy you know stocks Orilissa. Use Medfinder for Providers to check real-time inventory at nearby pharmacies.

Step 3: Connect Patients With Savings Programs at the Visit

Cost is a major driver of prescription abandonment for Orilissa. At the time of prescribing:

• Commercially insured patients: Provide information about the AbbVie Orilissa Savings Card (copay as low as $5/month). Patients can enroll at orilissa.com.
• Uninsured/underinsured patients: Refer to myAbbVie Assist (abbvie.com/myAbbVieAssist or 1-800-222-6885) for potential full medication coverage.
• Medicare/Medicaid patients: The savings card is not valid. Consider alternative therapies or state pharmaceutical assistance programs.

Step 4: Establish Specialty Pharmacy Relationships

Identify 1–2 specialty pharmacies that reliably stock Orilissa and work well with your practice. Benefits include:

• They handle PA and insurance navigation on your behalf.
• They can ship directly to the patient's home.
• They provide adherence monitoring and patient counseling.
• They're experienced with high-cost specialty medications.

Having a go-to specialty pharmacy eliminates the guesswork for both your staff and your patients.

Step 5: Provide Patients With a Backup Plan

Before the patient leaves, set expectations and provide resources:

• "It may take a few days for your insurance to approve this medication."
• "If the pharmacy doesn't have it, here's what to do..." — point them to Medfinder or give them the specialty pharmacy contact info.
• "If you can't get Orilissa within [timeframe], call us and we'll explore alternatives."

This proactive communication reduces patient anxiety and keeps them in the treatment pipeline.

Alternative Therapies When Orilissa Isn't Accessible

If access barriers prove insurmountable, consider these alternatives:

• Myfembree (Relugolix/Estradiol/Norethindrone acetate): Oral GnRH antagonist with add-back therapy. Similar mechanism with potential BMD advantages.
• Lupron Depot (Leuprolide): Injectable GnRH agonist. Monthly or quarterly dosing. Well-established efficacy.
• Norethindrone acetate 5 mg: Off-label oral progestin. Very affordable (under $30/month). Good for mild-moderate symptoms.
• Depo-Provera: Injectable progestin every 3 months. $50–$150 per injection. Also provides contraception.

See our detailed comparison: Alternatives to Orilissa.

Workflow Tips for Your Practice

• Create an Orilissa "prescribing packet": Include the savings card information, specialty pharmacy contacts, Medfinder instructions, and a patient-friendly FAQ. Hand this to every patient who receives an Orilissa prescription.
• Track PA outcomes: Monitor how long PAs take and which payers approve most consistently. This data helps you set realistic expectations with patients.
• Designate a staff member for specialty medication access: Whether it's an MA, nurse, or pharmacy liaison, having one person own the process reduces dropped balls.
• Follow up at 2 weeks: Check that the patient actually filled the prescription. If they haven't, intervene early — don't wait until the next appointment.

Final Thoughts

Prescribing Orilissa is only half the battle. Ensuring your patient can actually access it requires proactive steps at the point of care. By initiating prior authorization early, routing prescriptions to the right pharmacy, connecting patients with financial assistance, and building specialty pharmacy relationships, you can significantly reduce the access gap.

Visit Medfinder for Providers for real-time pharmacy inventory tools, and share our patient resources — like how to find Orilissa in stock — to empower patients in their own access journey.